Last updated: August 1, 2026
AbbVie’s federal patent case against Mylan in 1:14-cv-01288 is a file-history-based Orange Book patent dispute tied to Mylan’s proposed FDA product entry. The record type indicates a generic/brand infringement and Hatch-Waxman litigation track, typically resolved through a combination of claim construction, infringement/non-infringement rulings, and a resolution tied to launch timing rather than a full merits trial on every asserted patent.
No case-specific docket facts (asserted patent numbers, claim construction outcomes, court orders, settlement terms, and final disposition date) are included in the provided input. Without those docket-level details, a complete and accurate litigation summary cannot be produced.
What is AbbVie Inc. v. Mylan Pharmaceuticals Inc. (1:14-cv-01288) about?
Short answer: This is a Hatch-Waxman patent infringement action by AbbVie against Mylan tied to Mylan’s ANDA entry for a product implicated by AbbVie’s Orange Book-listed patents.
Which drug, ANDA, and Orange Book patents are involved?
A litigation summary requires the ANDA product name, ANDA number, and specific asserted U.S. patents listed in the complaint and referenced in the Paragraph IV certifications. Those identifying details are not present in the provided input.
What legal theories are typically asserted in this case type?
Hatch-Waxman generics cases commonly assert:
- Infringement of one or more U.S. patents listed in the Orange Book
- Declaratory judgment and injunction under 35 U.S.C. § 271(e)(2)
- Willful infringement or enhanced damages (depending on filings)
- Treaty or regulatory references only as background, not as core causes of action
What patents protect AbbVie’s product in the 1:14-cv-01288 dispute?
Short answer: Patent coverage is governed by the Orange Book listing(s) connected to AbbVie’s NDA and the patents actually asserted in the complaint.
How many patents were asserted and which assignees held them?
A correct answer requires:
- the list of asserted patent numbers in the complaint
- the assignee(s) shown on each patent
- whether AbbVie sued on composition, formulation, method-of-use, or manufacturing patents
These elements are not contained in the provided input.
What is the likely mix of patent types in AbbVie vs. Mylan actions?
AbbVie portfolios frequently litigate across:
- Composition-of-matter patents
- Formulation patents (including particle size, excipients, or stability)
- Method-of-use patents tied to dosing regimens or clinical endpoints
But the precise mix for 1:14-cv-01288 cannot be stated without the docket text.
When does AbbVie’s exclusivity expire for the product at issue in 1:14-cv-01288?
Short answer: Exclusivity timing depends on the NDA approval date, any pediatric exclusivity extensions, and the earliest Orange Book patent expiration tied to the litigation.
Does the litigation turn on patent expiration or exclusivity workarounds?
Hatch-Waxman cases often turn on one or more of:
- whether a challenged patent is valid and infringed
- whether a design-around or non-infringing formulation exists
- whether the proposed generic can enter before the “blocking” patent expires
No approval date, exclusivity type, or patent expiration dates are provided.
How strong is AbbVie’s patent estate versus Mylan’s generic entry risk in 1:14-cv-01288?
Short answer: Strength analysis requires the asserted patents, the court’s claim construction, and any invalidity/infringement rulings.
Key metrics used in courts for “strength”
- claim construction outcomes for the asserted limitations
- novelty/obviousness posture under the specific asserted references
- enablement and written description findings
- prosecution history and estoppel issues
None of these are included in the input.
What happened procedurally in AbbVie v. Mylan (1:14-cv-01288): TRO, preliminary injunction, summary judgment, or settlement?
Short answer: A case of this category typically proceeds through markman/claim construction and then either summary judgment, trial, or a stipulated dismissal post-resolution. The precise procedural posture and outcome cannot be determined from the provided input.
What would a litigation timeline require?
A complete timeline needs:
- complaint filing date
- answer/date of amended pleadings
- initial claim construction scheduling and orders
- summary judgment dates
- any injunction hearing dates
- settlement or dismissal order date
- final disposition (with or without prejudice)
Those timestamps are not present.
Did AbbVie file a Paragraph IV challenge, and did Mylan’s ANDA include a Section viii certification?
Short answer: In this litigation category, the case usually is anchored to a Paragraph IV certification tied to the ANDA referencing AbbVie’s Orange Book patents.
What must be known for a correct Paragraph IV analysis
- the specific Paragraph IV patent numbers
- whether Mylan also made Paragraph III (waiting for expiration) certifications
- whether any patents were withdrawn or delisted during litigation
None of this is in the input.
What is the current Orange Book status of AbbVie’s product patents at issue in 1:14-cv-01288?
Short answer: Orange Book status is determined by whether patents remain listed, have expired, have been delisted, or have been newly listed.
What needs to be documented for Orange Book status
- product name and NDA number
- patent numbers and expiration dates
- patent listing types (drug substance, drug product, method-of-use)
- whether any patents were “expired” or “withdrawn” during the litigation window
The input does not include the product identifiers.
What generic entry risks existed for Mylan if the asserted patents were invalid or not infringed?
Short answer: Generic entry risk is driven by:
- which patents are “blocking”
- whether the generic design avoids literal infringement or satisfies non-infringement positions
- whether the court enjoins launch pending appeal
No asserted patents or infringement outcomes are provided.
How does AbbVie v. Mylan compare with similar AbbVie Hatch-Waxman cases?
Short answer: Comparison depends on cross-case docket data such as asserted patent families, adjudicated claim constructions, and settlement patterns across the same product portfolio. That information is not present.
Key Takeaways
- 1:14-cv-01288 is an AbbVie vs. Mylan Hatch-Waxman-style patent infringement dispute connected to an ANDA/Orange Book framework.
- A complete litigation summary requires docket-level specifics: asserted patent numbers, ANDA/product identifiers, procedural orders, and final disposition.
- Those required inputs are not included in the provided prompt, so an accurate, case-specific litigation narrative cannot be produced.
FAQs
- What court orders typically decide a Hatch-Waxman case like AbbVie v. Mylan (1:14-cv-01288)?
- How do claim construction outcomes usually affect infringement analysis in ANDA patent cases?
- What settlement outcomes are common in AbbVie-style Orange Book patent disputes with generics?
- What does “blocking” patent mean in the context of FDA ANDA timing and launch eligibility?
- How do method-of-use and formulation patents differ in infringement proofs for generic products?
References
- (No citable sources were provided in the prompt.)
